



Edition: BP 2025 (Ph. Eur. 11.6 update)

Menadiol Phosphate Tablets

[General Notices](#)

Action and use

Vitamin K analogue.

DEFINITION

Menadiol Phosphate Tablets contain Menadiol Sodium Phosphate.

The tablets comply with the requirements stated under Tablets and with the following requirements.

Content of menadiol phosphate, $C_{11}H_{12}O_8P_2$

92.5 to 107.5% of the stated amount.

IDENTIFICATION

A. Shake a quantity of the powdered tablets containing the equivalent of 0.15 g of menadiol phosphate with 15 mL of [water](#), centrifuge and filter the supernatant liquid. To 10 mL of the filtrate add 10 mL of 1M [sulfuric acid](#), 10 mL of 0.1M [cerium\(IV\) sulfate](#) and 1 mL of [hydrogen peroxide solution \(20 vol\)](#) and extract with two 10 mL quantities of [chloroform](#). Evaporate the combined chloroform extracts to dryness in a water bath and dry the residue at 40° at a pressure not exceeding 0.7 kPa. The [infrared absorption spectrum](#) of the residue, [Appendix II A](#), is concordant with the *reference spectrum* of menadione ([RS 214](#)).

B. To 50 mg of the residue obtained in test A add 5 mL of [water](#) followed by 75 mg of [sodium metabisulfite](#), heat in a water bath, shaking vigorously, until an almost colourless solution is obtained and dilute to 50 mL with [water](#). To 2 mL of the resulting solution add 2 mL of a mixture of equal volumes of 13.5M [ammonia](#) and [ethanol \(96%\)](#), shake and add 0.15 mL of [ethyl cyanoacetate](#). A deep purplish-blue colour is produced which changes to green on the addition of 1 mL of 10M [sodium hydroxide](#).

TESTS

Related substances

Carry out in subdued light the method for [thin-layer chromatography](#), [Appendix III A](#), using [silica gel](#) GF₂₅₄ as the coating substance and a mixture of 50 volumes of [propan-1-ol](#), 50 volumes of a 2% w/v solution of [ammonium chloride](#), 5 volumes of [butan-1-ol](#) and 1.5 volumes of [diethylamine](#) as the mobile phase. Apply separately to the plate 5 µL of each of the following solutions. For solution (1) shake a quantity of the powdered tablets containing the equivalent of 0.25 g of menadiol phosphate with 10 mL of [methanol](#) (50%) and filter. For solution (2) dilute 1 volume of solution (1) to 200 volumes with [methanol](#) (50%). Solution (3) contains 0.0080% w/v of [2-methyl-1,4-naphthoquinone](#) in [methanol](#). After removal of the plate, allow it to dry in air and examine under [ultraviolet light \(254 nm\)](#). Any [secondary spot](#) in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (3). Examine the plate under [ultraviolet light \(365 nm\)](#). Any [secondary spot](#) in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (2).

ASSAY

Weigh and powder 20 tablets. Shake a quantity of the powder containing the equivalent of 10 mg of menadiol phosphate with 100 mL of 0.1M [hydrochloric acid](#) for 30 minutes. Dilute to 250 mL with 0.1M [hydrochloric acid](#), filter and measure the [absorbance](#) of the filtrate at the maximum at 290 nm, [Appendix II B](#). Calculate the content of $C_{11}H_{12}O_8P_2$ taking the value of $A(1\%, 1\text{ cm})$, for a solution of $C_{11}H_8Na_4O_8P_2$ in 0.1M [hydrochloric acid](#), to be 138 at the maximum at 290 nm. Each mg of $C_{11}H_8Na_4O_8P_2$ (menadiol sodium phosphate) is equivalent to 0.792 mg of $C_{11}H_{12}O_8P_2$ (menadiol phosphate).

LABELLING

The quantity of active ingredient is stated in terms of the equivalent amount of menadiol phosphate.